116. Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results from the POLAR Study

BACKGROUND: Long-acting (LA) cabotegravir (CAB) and rilpivirine (RPV) injectable suspensions have demonstrated efficacy in phase III studies. POLAR assessed antiviral activity and safety of CAB LA+RPV LA, administered every 2 mos (Q2M), in HIV-1 infected, antiretroviral therapy–experienced adults wh...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Open Forum Infect Dis
Main Authors: Mills, Anthony, Richmond, Gary J, Newman, Cheryl, Osiyemi, Olayemi, Cade, Jerry, Brinson, Cynthia, De Vente, Jerome, Andany, Nisha, Margolis, David, Sutton, Kenneth, Wilches, Viviana, Roberts, Jeremy, McCoig, Cynthia C, Vandermeulen, Kati, Spreen, William
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Poster Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7778199/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa439.426
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados